Holen Sie sich die Stockscreener-App
199.48
2.22%
-4.5203
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$204.00
Offen:
$205.28
24-Stunden-Volumen:
485.65K
Relative Volume:
0.49
Marktkapitalisierung:
$22.14B
Einnahmen:
$11.04B
Nettoeinkommen (Verlust:
$1.04B
KGV:
22.76
EPS:
8.7626
Netto-Cashflow:
$1.36B
1W Leistung:
+4.18%
1M Leistung:
+1.98%
6M Leistung:
+8.86%
1J Leistung:
+14.92%
1-Tages-Spanne:
$197.59
$205.66
1-Wochen-Bereich:
$190.23
$209.79
52-Wochen-Spanne:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
199.42 | 22.76B | 11.04B | 1.04B | 1.36B | 8.7626 |
TMO
Thermo Fisher Scientific Inc
|
460.67 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.91 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.81 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
113.64 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.52 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Merck & Company (MRK) - The Globe and Mail
Quest Diagnostics (NYSE: DGX) boosts Q1 2026 earnings on 11% volume growth - Stock Titan
Quest Diagnostics Stock Gains 5% After Q1 Earnings Exceed Analyst Expectations - TIKR.com
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2026 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $229 From $224, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance - GuruFocus
Quest Diagnostics rises after raising 2026 outlook following Q1 beat - MSN
Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF Value Says Overvalued - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Jefferies Raises Quest Diagnostics Price Target to $225 From $220 - marketscreener.com
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics raises guidance following earnings beat - marketscreener.com
Quest Diagnostics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Quest Diagnostics raises 2026 forecast, CEO highlights broad-based growth - marketscreener.com
Valmont Industries posts upbeat Q1 results, joins UnitedHealth Group, Quest Diagnostics and other big stocks moving higher on Tuesday - MSN
Quest Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
Valmont Industries Posts Upbeat Q1 Results, Joins UnitedHealth Group, Quest Diagnostics And Other Big Sto - Benzinga
Quest Diagnostics Q1 2026 Earnings Call: Complete TranscriptQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up - Yahoo Finance
Q1 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Quest Diagnostics raises full-year forecast, posts strong quarter on testing demand - marketscreener.com
Quest Diagnostics: Q1 Earnings Snapshot - marketscreener.com
Quest Diagnostics Inc (NYSE:DGX) Beats Q1 2026 Estimates and Raises Full-Year Guidance - ChartMill
Quest Diagnostics Q1 Adjusted Earnings, Revenue Rise; Full-Year Outlook Upgraded -- Shares Up Pre-Bell - marketscreener.com
Quest Diagnostics stock up 3% on earnings beat, raised guidance By Investing.com - Investing.com Canada
Is Quest Diagnostics (DGX) Overvalued After Q1 2026 Earnings Bea - GuruFocus
(DGX) Quest Diagnostics Expects 2026 Revenue Range $11.78B$11.90B, vs. FactSet Est of $11.76B - marketscreener.com
(DGX) Quest Diagnostics Expects 2026 Adjusted EPS Range $10.63$10.83, vs. FactSet Est of $10.63 - marketscreener.com
Quest’s (NYSE:DGX) Q1 CY2026 Sales Beat Estimates - TradingView
Earnings Flash (DGX) Quest Diagnostics Incorporated Reports Q1 Revenue $2.90B, vs. FactSet Est of $2.83B - marketscreener.com
Earnings Flash (DGX) Quest Diagnostics Incorporated Posts Q1 Adjusted EPS $2.50 per Share, vs. FactSet Est of $2.37 - marketscreener.com
Quest Diagnostics (NYSE: DGX) posts Q1 2026 growth and raises full-year outlook - Stock Titan
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 - PR Newswire
Quest Diagnostics earnings on deck as margin expansion eyed By Investing.com - Investing.com Canada
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Quest Diagnostics (DGX) Sees Premarket Surge Amid Market Volatility - GuruFocus
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
City of Hope to track 500 patients with blood test for earlier recurrence - Stock Titan
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings - Yahoo Finance
Quest Diagnostics Mirrors S&P 500 Index Sector Momentum Clearly - Kalkine Media
Baird Adjusts Price Target on Quest Diagnostics to $224 From $219, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Patton Fund Management Inc. Has $5.56 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Atwater Malick LLC - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):